Bridgewater, NJ, United States of America

Shaoqing Chen

This inventor holds 20 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Hoffmann-La Roche Inc., Roche Palo Alto LLC, Takeda Pharmaceutical Company Limited. Active years: 2006-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shaoqing Chen. Retrieved from https://idiyas.com/inventor/shaoqing-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20 (Patent Applications = 2)

% Patents Active = 10.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 27(Granted Patents)

Company Filing History:

19 out of 5,026

Hoffmann-La Roche Inc.

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2006-2018

Loading Chart...

Areas of Expertise:

Tetrahydro-benzodiazepinones

IRAK4 Modulators

Thienopyrimidine Compounds

Substituted Sulfonamide Compounds

Pyrrolopyrazine Inhibitors

Thiazolyl-benzimidazoles

Halo-substituted Pyrimidodiazepines

Quinazoline Thiazolinones

Glucokinase Activators

GFAT Inhibitors

Thiazolinone Quinolines

Azaindole Compounds

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10053431 - Tetrahydro-benzodiazepinones (2018-08-21),

2. 10023589 - Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators (2018-07-17),

3. 9701691 - Thienopyrimidine compounds (2017-07-11),

4. 9580411 - Substituted sulfonamide compounds (2017-02-28),

5. 9255110 - Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators (2016-02-09),

6. 8658646 - Pyrrolopyrazine kinase inhibitors (2014-02-25),

7. 8063085 - Substituted hydantoins (2011-11-22),

8. 8044213 - Thiazolyl-benzimidazoles (2011-10-25),

9. 8003785 - Halo-substituted pyrimidodiazepines (2011-08-23),

10. 7612212 - Substituted hydantoins (2009-11-03),

11. 7557221 - Substituted hydantoins (2009-07-07),

12. 7517873 - Substituted pyrimidodiazepines (2009-04-14),

13. 7501428 - Quinazoline thiazolinones (2009-03-10),

14. 7326786 - Thiazolinone unsubstituted quinolines (2008-02-05),

15. 7253285 - Thiazolinone 4-monosubstituted quinolines (2007-08-07),

Title: Innovator in Pharmaceutical Chemistry: Shaoqing Chen

Introduction

Shaoqing Chen is a prolific inventor based in Bridgewater, NJ, known for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 20 patents, Chen has established himself as a key figure in developing innovative treatments for various medical conditions.

Latest Patents

Among his latest patents, Chen has introduced groundbreaking compounds such as Tetrahydro-benzodiazepinones, which encompass compounds of Formula I, or pharmaceutically acceptable salts thereof. These compounds are essential for potential applications in cancer treatment. Additionally, he has developed Pyrazolo[1,5a]pyrimidine derivatives that serve as IRAK4 modulators, demonstrating effectiveness in the treatment of IRAK-mediated conditions.

Career Highlights

Chen has had a distinguished career working with esteemed organizations, including Hoffmann-La Roche Inc. and Roche Palo Alto LLC. His innovative approach to pharmaceutical research has led to the development of crucial compounds that address significant health challenges.

Collaborations

Throughout his career, Shaoqing Chen has collaborated with talented colleagues such as Steven Gregory Mischke and Li Chen. These partnerships have fostered an environment of innovation, contributing to the advancement of drug development and therapeutic strategies.

Conclusion

As an influential inventor in the realm of pharmaceutical chemistry, Shaoqing Chen continues to impact the industry positively. His commitment to research and discovery exemplifies the spirit of innovation, as he works to develop effective treatments that can change lives.

Profile summary based on public USPTO records.